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Abstract 
The EPO-TBI study randomised 606 patients with moderate or severe traumatic brain injury 
(TBI) to be treated with weekly epoetin alfa (EPO) or placebo. Six-month mortality was 
lower in EPO treated patients in an analysis adjusting for TBI severity. Knowledge of possible 
differential effects by TBI injury subtype and acute neurosurgical treatment as well as timing 
and cause of death (COD) will facilitate the design of future interventional TBI trials. We 
defined COD as cerebral (brain death, cerebral death with withdrawal or death during 
maximal care) and non-cerebral (death following withdrawal or during maximal care due to 
a non-cerebral cause). The study included 305 patients treated with EPO and 297 with 
placebo, with COD recorded in 77 (99%) out of 78 non-survivors. Median time to death in 
patients dying of cerebral COD was 8 days (IQR 5-16) compared to 29 days (IQR 7-56) 
(p=0.01) with non-cerebral COD. When assessing subgroups by admission computed 
tomography scan injury findings, we found no significant differential effects of EPO 
compared to placebo. However, EPO appeared more effective in patients with an injury type 
not requiring a neurosurgical operation prior to ICU admission (OR 0.29, 95% confidence 
interval 0.14-0.61, p=0.001, p for interaction = 0.003) and in this sub-group, fewer patients 
died of cerebral causes in in the EPO compared to placebo group (5% compared to 14%, 
p=0.03). In conclusion, most TBI deaths were due to cerebral causesthat occurred during the 
first two weeks, and were related to withdrawal of care. EPO appeared to specifically reduce 
cerebral deaths in the important subgroup of patients with a diffuse type of injury not 
requiring a neurosurgical intervention prior to randomisation. 
Key words: traumatic brain injury, clinical management of CNS injury, head 
trauma, human studies, adult brain injury 
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 Introduction 
 Traumatic brain injury (TBI) is a leading cause of morbidity and mortality among young 
people.
1
 The mainstay of treatment is rapid transfer to designated and specialised trauma 
centres with both neurosurgical and neurointensive care expertise.
2
 Mortality after severe 
TBI remains high in the range of 20-40%,
3
 and many pharmacological interventions to 
ameliorate secondary brain injury have been evaluated without success.
4, 5
 Timing of death 
after trauma and TBI is frequently described as early or late.
6
 Early deaths are related to 
either brain death or treatment withdrawal due to a perceived poor prognosis,
7
 whereas 
late deaths are believed  to be mainly due to infection and multi-organ failure.
8
   
 In the EPO-TBI trial, 606 critically ill patients with moderate or severe TBI were randomized 
to the administration of epoetin alfa or placebo.
9
 While, the study failed to show an 
improvement in neurological function at six months, it did demonstrate a significant 
decrease in mortality with EP  administration in a pre-specified analysis. Interestingly 
similar beneficial effects of EPO in trauma and TBI patients were demonstrated in two 
previous randomized, placebo-controlled trials.
10, 11
  
  
The mechanisms behind this potential decrease in mortality are currently unknown. 
However, detailed knowledge on timing of death and probable cause of death is logically 
important for the design of future interventional studies of critically ill TBI patients and 
might also shed some light on why EPO seems to lower mortality after major trauma. 
Moreover, given the heterogeneity of both TBI type and neurosurgical treatment, it is 
possible that there are TBI sub-groups in which EPO is more effective than in others. In the 
current study, we primarily aimed to explored timing and cause of death in patients treated 
with EPO or placebo after major or severe TBI. Secondarily we aimed to assess relationships 
between TBI specific sub-groups and neurosurgical care and intervention effect.  
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Methods 
 The EPO-TBI trial was a multi-centre, multi-national, randomised, double-blind, parallel-
group, placebo controlled trial that enrolled 606 patients with non-penetrating moderate 
(best post-resuscitation, pre-intubation Glasgow Coma Score [GCS] 9-12) or severe (GCS 3-8) 
TBI 
9
 Study centres from Australia, New Zealand, Saudi-Arabia, France, Finland, Germany 
and Ireland participated.  Within 24 hours of ICU admission patients were randomised to 
receive either weekly doses of 40,000 IU of subcutaneous epoetin alfa (Eprex Janssen-Cilag 
Pty Ltd, Titusville, NJ, USA) or placebo (0.9% sodium chloride) for a maximum of three doses 
or until the patients was discharged from the ICU
12
  
 
Data collection  
A web based case record form was used including detailed data on patient characteristics, 
injury mechanism, pre-hospital care and immediate hospital management.
12
 Specifically 
data enabling the calculation of the International Mission for Prognosis and Analysis of 
Clinical Trials in TBI (IMPACT-TBI) risk for poor six month outcome was included.
13
 Trained 
assessors classified injury severity with Injury Severity Scores (ISS), Abbreviated Injury Scales 
(AIS) based on radiological findings and hospital notes. Data on performed neurosurgical 
procedures included daily assessment of whether the patient received any neurosurgical 
procedure such as mass lesion removal, craniectomy or bifrontal decompressive 
craniectomy. Data on neuro-intensive care included daily assessment of whether 
intracerebral pressure was monitored, patient received hyperventilation or whether 
induced hypothermia was in use.   
 
Trial outcome and cause of death 
The primary outcome of the EPO-TBI trial was neurological function at six months 
categorized with the Glasgow Outcome Scale Extended (GOSE). A good outcome was 
defined as a GOSE score from 5 to 8. Time of death was recorded prospectively and 
categorised into the following five different categories: 1. Brain death; 2. Death with 
therapy withdrawn for severe cerebral damage; 3. Death with therapy withdrawn for non-
cerebral reasons (e.g. multiorgan failure [MOF]); 4. Death despite maximal support for 
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severe cerebral damage, and 5. Death despite maximal support for non-cerebral reasons 
(e.g. MOF)
12
  
For the analysis, brain death and other deaths categorised as cerebral were included as one 
group i.e. “cerebral deaths”. Similarly, the two non-cerebral death groups were categorised 
as “non-cerebral”. Admission computed tomography (CT) scans were viewed by an assessor 
blinded to treatment and categorised according to the Marshall category.
14
 As in previous 
studies we grouped together Marshall groups V and VI.
15, 16
 
 
Statistical analysis 
Categorical data are presented as numbers and percentages and compared using chi-square 
test. Numerical data are presented as means and standard deviation (SD) or as medians and 
interquartile range (IQR) in parenthesis. Parametric data is compared with a Student’s T test 
and non-parametric data with the Mann-Whitney U or Kruskall-Wallis test. Kaplan-Meier 
curves for both cerebral and non-cerebral deaths were constructed and compared between 
the EPO and placebo treated patients with a log-rank test. The effect of intervention on 6-
month mortality was determined using logistic regression and reported as odds ratios with 
95% confidence intervals, while heterogeneity between subgroups was determined by 
fitting an interaction between treatment and sub-group. A p-value less than 0.05 was 
considered significant. Statistical analysis was performed with SPSS version 22.0 (IBM Corp. 
Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.) and 
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). 
 
Ethical permits, consent and trial registration 
The main study had ethical approvals at all sites. Consent was obtained from the patient 
next of kin or legal representative prior to study inclusion. The trial was registered at 
ClinicalTrials.gov (number NCT00987454), the Australian and New Zealand Clinical Trials 
Registry (number ACTRN12609000827235), and European Drug Regulatory Authorities 
Clinical Trials (number011-005235-22). 
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Results 
 A total of 606 patients were included in the study. Consent was withdrawn in three patients 
and one was lost to follow-up, leaving 602 analysable patients. A total of 78 patients (13%) 
died prior to 6 months, 59 patients (76%) died while in the ICU, 11 (14%) while in the 
hospital and 8 patients (10%) after hospital discharge. A total of 32 deaths (41%) occurred 
during the first week, 20 during the second week (26%) and 26 patients (33%) later than two 
weeks (Fig.1).  
Differences in clinical characteristics between cerebral and non-cerebral deaths  
 The cause of death (COD) was recorded in 77 (99%) out of 78 patients. Of the 77 deaths, 62 
(80%) were due to cerebral reasons and 15 (20%) due to non-cerebral reasons. There were 
minimal differences in admission characteristics in patients who died from cerebral reasons 
compared to those dying from non-cerebral reasons (Table 1). Regarding CT findings and 
COD, only petechial haemorrhages were more common in patients dying from a cerebral 
COD (Table 2).  Median time to death in patients dying of cerebral reasons was 8 days (IQR 
5-16) and in those with non-cerebral reasons it was 29 days (IQR 7-56) (p=0.01). 
 Of the 62 cerebral deaths, 16 (26%) were due to brain death, 7 (11%) due to cerebral causes 
during maximal support and 39 (65%) due to withdrawal of care (Supplemental Table 1 and 
2). Of the non-cerebral deaths 7 occurred during (47%) maximal support and in the 
remaining 8 (53%), due to withdrawal of care (Supplemental Table 1 and 2). A total of 47 
(60%) out of 77 deaths were due to treatment withdrawal. Median time to death in those in 
whom treatment was withdrawn was 11 days (IQR 7-32) and in those who died with full 
support it was 7 days (IQR 4-10). There were significant differences in clinical characteristics 
and CT findings in the non-survivors with different COD (Supplemental Tables 1 and 2). 
Notably patients dying from brain death were younger and had more episodes of raised ICP.    
Effect of EPO or placebo on cause and timing of death 
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 During ICU stay, 24 (7.9%) of 305 EPO treated patients died compared to 35 (11.7%) of 297 
treated with placebo (p=0.11). During hospital care 28 (9.2%) of EPO treated patients had 
died compared to 42 (14.1%) treated with placebo (p=0.06).  At six months 32 (10.5%) out of 
305 EPO treated patients had died compared to 46 (15.5%) out of 297 treated with placebo 
(p=0.07). The causes of death in EPO and placebo treated patients are shown in Table 3. 
There was no difference in the distribution of causes of death for EPO and placebo treated 
patients (p=0.44). Survival curves for cerebral and non-cerebral deaths according to the use 
of EPO or placebo were similar (Supplemental Fig. 1). Time to death was 11 days (7-28) in 
the EPO treatment group and 8 days (IQR 5-18) in the placebo group (p=0.11). Among the 
EPO treated patients, death was due to withdrawal of care in 21 (6.9%) out of 305 patients, 
and the corresponding figure for the placebo treated patients was 27 (9.1%) out of 298 
patients (p=0.32).          
Effect of EPO by admission CT characteristics and neurosurgical operation  
 The effect of EPO indexed by admission CT findings and neurosurgical treatment are shown 
in Fig. 2 and Fig. 3. There were no significant differences in treatment effect of EPO 
according to different subtypes of admission CT brain findings (Fig. 2). There was no 
differential effect indexed by use of ICP monitoring, hyperventilation or hypothermia during 
ICU care (Fig. 3). 
 There was, however, a strong differential effect of EPO in patients that had not undergone 
a neurosurgical procedure prior to randomisation compared to those who had (Fig. 3). In 
the group that did not have a neurosurgical operation, EPO decreased mortality (OR 0.29 95% 
CI 1.14-0.61, p=0.01) compared to those who had (OR 1.39 95% CI 0.68-2.85, p=0.37) (p for 
interaction 0.003). Survival curves indexed for the non-neurosurgical group and the 
neurosurgical groups are shown in Fig. 4. In the non-neurosurgical group, the proportion of 
patients with good outcome at 6 months appeared higher in the EPO group (64% compared 
to 58%, p00.25) but this difference was not statistically significant. The distribution of GOSE 
scores in the non-neurosurgical group treated with EPO or placebo are shown in the 
Supplementary Appendix (Supplemental Fig. 2). In the neurosurgical group, the proportion 
of patients with good outcome at 6 months appeared lower with EPO compared to placebo 
(40% compared to 52%, p=0.23) but this difference was not statistically significant  
 The COD by intervention indexed by neurosurgical group and non-neurosurgical groups are 
shown in Table 3. There was a significant differences in the distribution of COD between 
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patients treated with EPO compared to placebo in the non-neurosurgical group, but not in 
the neurosurgical group (Table 3). Cerebral deaths occurred in 10 (5%) out of 197 patients 
treated with EPO, and in 28 out of 203 (14%) treated with placebo (p=0.003). 
 
Discussion 
 In this population of critically ill patients included in a randomised controlled trial (RCT) of 
TBI therapy, the majority of deaths occurred during the first two weeks following injury and 
were cerebral in nature. Death was commonly related to withdrawal of treatment, and only 
a smaller proportion died while receiving maximal medical intervention. Death due to non-
cerebral reasons occurred later during the hospital course.  We found overall no difference 
in causes or timing of death between EPO and placebo treated patients. However, with 
regards to different types of TBI and requirement of neurosurgical interventions, we found 
that EPO appeared significantly more effective than placebo in patients not receiving a 
neurosurgical operation prior to randomisation. In this subgroup, EPO appeared to 
especially decrease the rates of death from a cerebral cause and EPO did not appear to 
increase the proportion of survivors in a poor neurological state. These findings have 
implications for future studies on EPO in TBI patients.   
 The overall mortality of 13% found in the present study was slightly lower than in several 
previous studies.
17, 18
 In a recent large pharmacological study on the use of progesterone in 
TBI, the six month mortality was 17%, and in trials of ICP monitoring and decompressive 
craniectomy six month mortality was substantially higher ranging from 30%-48%
18, 19
 In a 
study evaluating prehospital administration of hypertonic saline to TBI patients, mortality 
was even higher.
20
 Patients with this severity of injury are not likely to have been included in 
the current EPO-TBI trial given the inclusion of patients with moderate TBI and the exclusion 
of patients, who according to the treating clinician are likely to die within the next 48 
hours.
12
 In prospective observational studies, six month mortality has been shown to range 
from 25% to 44%.
21-23
 In the current study, non-cerebral deaths occurred significantly later 
than cerebral deaths. This supports the hypothesis that late deaths are related to multi-
organ failure and sepsis.
8
 
 We have demonstrated that most deaths were due to withdrawal of treatment, irrespective 
whether the death was attributed to a cerebral or non-cerebral cause. In a prospective 
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Canadian cross sectional study the number of TBI deaths associated with withdrawal ranged 
from 45% to 90%. In the current study treatment withdrawal was more common with higher 
age, lower level of consciousness at presentation and a more severe TBI, in line with findings 
by Turgeon and colleagues.
23
 In the study by Turgeon and colleagues withdrawal most 
commonly occurred within the first three days of intensive care
23
 but in our international 
multicentre randomized controlled trial, time to death related to withdrawal was longer. 
The death rate following withdrawal of medical treatment is infrequently reported in 
RCTs.
15
 This mode of death represents a major challenge for the design of future 
interventional TBI trials and reinforces the need for treatment blinding where feasible. In 
the current study we observed no difference in the proportion of treatment withdrawal or 
time to withdrawal between EPO and placebo treated patients.  
 TBI is without doubt a heterogeneous disease as evidenced by the different possible 
pathological findings on the admission CT scan.
24
 Indeed the heterogeneity of TBI has been 
seen as one reason behind the failures of pharmacological trials performed to date.
25, 26
 In 
the SYNAPSE trial where TBI patients were administered progesterone after TBI, the main 
results of the trial was negative, and even extensive sub-group analysis including different 
admission Marshall Classification, decompressive craniectomy, or the need for surgery did 
not change the results.
27
 In the recent trial on the use of therapeutic hypothermia for the 
treatment of raised ICP, a post hoc analysis revealed that hypothermia was more harmful in 
patients with less severe TBI, and did not provide beneficial effects with more severe 
injury
28
.  
 In the current study, we observed no difference in frequency of cerebral or non-cerebral 
deaths between EPO and placebo treated patients in the whole sample. We did however 
observe a striking differential effect of EPO in the patients admitted to the ICU that had not 
undergone a neurosurgical operation prior to randomisation. In this sub-cohort EPO 
appeared to decrease the incidence of cerebral deaths. Non-neurosurgical patients are 
those with diffuse injury, petechial haemorrhages, and with small haemorrhages not 
appropriate for neurosurgical evacuations. The proposed mechanism of why EPO could 
work include a decrease in local tissue hypoxia in the brain, or a decrease in cerebral 
oedema due to improved function of the blood-brain barrier, and an attenuation of 
secondary brain injury, which may occur with all types of TBI.
29, 30
 Presence of a mass lesion 
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necessitating immediate surgery is a confounder and may have a major independent effect 
on survival. In contrast, in patients receiving medical therapy only, EPO may provide a 
degree of independent protective effect. Our study findings indicate that future trials using 
EPO for neuroprotection in TBI, may need to focus on patients with diffuse injury not likely 
to require a neurosurgical operation.  
 Strengths of the current study include a large multicentre randomised double blinded 
controlled trial with extensive prospective data collection and classification of admission CT 
scan findings by trained assessors unaware of treatment assignment. Moreover, all 
decisions on clinical management including withdrawal of care were made by clinicians 
unaware of treatment allocation. Finally, our findings of a specific effect in patients who did 
not receive neurosurgery prior to randomization suggest that identification of this specific 
high yield group could be introduced in a future interventional trial. Nonetheless, our study 
has certain limitations. Firstly, the performed analysis was not pre-planned, and with 
multiple testing the risk of finding significant treatment effects by chance increases. 
Therefore, our findings should be seen as hypothesis generating. Secondly, we do not have 
detailed data on autopsy results of the deceased patients and therefore the data on COD 
were ascertained clinically. Determining cause of death based on clinical scenarios is difficult 
and inter-rater disagreement is not uncommon. 
31
      
In conclusion, we have demonstrated that, in patients treated for moderate or severe TBI, a 
large majority of deaths are due to cerebral injury and occur during the first two weeks, 
whereas deaths due to non-cerebral causes occur after two weeks. Most deaths are related 
to treatment withdrawal, which represents a challenge for future trials of pharmacologic 
interventions in TBI. No distinct pattern in cause or time of death in patients treated with 
EPO or placebo was seen. However, there was a significantly lower mortality with EPO in the 
65% of patients who had not undergone a neurosurgical operation prior to randomisation.  
Our findings are likely to assist the identification of patients most likely to achieve increased 
survival with EPO treatment and inform the design of more targeted trials of EPO and other 
interventions in TBI.  
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TABLE 1. CHARACTERISTICS OF SURVIVORS AND NON-SURVIVORS BY CAUSE OF DEATH 
Data on survival missing in one patients and cause of death missing in one patient. Data on survival missing in one 
patients and cause of death missing in one patient. *p<0.05 for comparison between cerebral and non-cerebral cause 
of death. Neurosurgical and ICU interventions refer to any intervention taken place during stay in the intensive care 
unit.   
 Alive at six months 
(n=524) 
Cerebral deaths (n=62) Non-cerebral deaths (n=15) 
Patient characteristics    
   Mean age (years)
 
30 (22-46) 43 (23-55) 52 (41-58) 
   Female gender 87 (17%) 10 (16%) 4 (27%) 
Consciousness    
  Initial GCS
 
7 (5-9) 4 (3-7) 6 (4-10) 
Pupillary abnormality    
   Both equal and reacting 435 (83%) 42 (68%) 9 (60%) 
   Both dilated and non- 
reactive* 
0 (0%) 0 (0%) 1 (7%) 
  Both non-reactive 35 (7%) 9 (15%) 3 (20%) 
  One non-reactive 46 (9%) 10 (16%) 2 (13%) 
   Untestable/not 
documented 
8 (2%) 1 (2%) 0 (0%) 
Pre-hospital vital signs    
   Systolic blood pressure 
less than 90 mmHg 163 (31%) 23 (37%) 3 (20%) 
   Oxygen saturation less 
than 90% 97 (19%) 15 (24%) 3 (20%) 
Injury severity    
IMPACT probability of poor 
outcome 
19% (12-34%) 45% (28-59%) 28% (23-65%) 
APACHE II score 19 (14-24) 25 (20-30) 21 (16-27) 
Injury severity score 26 (18-33) 27 (22-33) 21 (17-35) 
Transfusion prior to 
randomisation 
   
   Red cells (%) 128 24%) 21 (34%) 5 (33%) 
   Platelets (%) 43 (8%) 11 (18%) 3 (20%) 
   Fresh frozen plasma (%) 78 (15%) 11 (18%) 2 (13%) 
   Other clotting product 
(%) 
40 (8%) 4 (7%) 1 (7%) 
   None (%) 374 (71%) 37 (60%) 9 (60%) 
Neurosurgical 
interventions 
   
   Mass lesion evacuated 161 (31%) 22 (36%) 5 (33%) 
   Craniectomy 104 (20%) 16 (26%) 6 (40%) 
   Bifrontal decompressive 
craniectomy 
17 (3%) 5 (8%) 0 (0%) 
ICU interventions    
   ICP use
  
352 (67%) 56 (90%) 13 (87%) 
   Proportion ICP end hours 
over 20 mmHg
 3% (0-9%) 14% (5-40%) 5% (4-20%) 
  Hypothermia
 
76 (15%) 26 (42%) 4 (27%) 
  Hyperventilation used*
 
243 (46%) 49 (79%) 6 (40%) 
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TABLE 2. FINDINGS ON INITIAL COMPUTED TOMOGRAPHY SCANS IN PATIENTS ACCORDING 
TO SIX MONTHS SURVIVAL AND CEREBRAL AND NON-CEREBRAL CAUSE OF DEATH.   
Data on survival missing in one patients and cause of death missing in one patient. *p<0.05 for comparison between 
cerebral and non-cerebral cause of death. The Marshall category Mass lesion includes both evacuated and non-
evacuated lesions noted on the first computed tomography scan.  
 
 Alive at six months 
(n=524) 
Dead at six-months (n=78) 
Cerebral deaths  (n=62) Non-cerebral deaths (n=15) 
CT findings    
   Subdural hematoma 248 (47%) 41 (66%) 11 (73%) 
   Extradural haematoma 114 (22%) 10 (16%) 5 (33%) 
  Contusion 360 (69%) 48 (77%) 10 (67%) 
   Intracerebral haemorrhage 135 (26%) 34 (55%) 6 (40%) 
   Subarachnoid haemorrhage 342 (65%) 54 (87%) 12 (80%) 
   Intraventricular haemorrhage 208 (40%) 28 (45%) 8 (53%) 
   Petechial haemorrhage* 156 (30%) 36 (58%) 3 (20%) 
   Midline shift (%) 147 (28%) 28 (45%) 9 (60%) 
   Midline shift (mm) 0 (0-1) 0 (0-1) 1 (0-1) 
   Basal cisterns 
     Normal 
     Compressed 
     Absent 
 
400 (76%) 
113 (22%) 
11 (2%) 
 
25 40%) 
33 (53%) 
4 (7%) 
 
7 (47%) 
7 (47%) 
1 (7%) 
Marshall category 
   Diffuse injury I 
   Diffuse Injury II 
   Diffuse Injury III 
   Diffuse Injury IV 
   Mass lesion 
 
23 (4%) 
337 (64%) 
44 (8%) 
16 (3%) 
104 (20%) 
 
 
0 (0%) 
21 (34%) 
21 (34%) 
5 (8%) 
15 (24%) 
 
 
0 (0%) 
6 (40%) 
2 (13%) 
2 (13%) 
5 (33%) 
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TABLE 3. CAUSE OF DEATH FOLLOWING MODERATE TO SEVERE TRAUMATIC BRAIN INJURY IN 
THE EPO-TBI STUDY INDEXED BY NEUROSURGICAL OR NON-NEUROSURGICAL GROUPS. 
 
 
 EPO Placebo p-value 
Cause of death in all randomized patients     
   Brain death 7 9 
0.44 
   Death with therapy withdrawn for severe   cerebral 
damage 
16 23 
   Death with therapy withdrawn for non-cerebral 
reasons 
4 4 
   Death with maximal support for severe cerebral 
damage 
2 5 
   Death with maximal support for non-cerebral reasons 2 5 
Cause of death in the neurosurgical group     
   Brain death 2 1 
0.59 
   Death with therapy withdrawn for severe   
cerebral damage 
12 8 
   Death with therapy withdrawn for non-cerebral 
reasons 
4 1 
   Death with maximal support for severe cerebral 
damage 
1 0 
   Death with maximal support for non-cerebral 
reasons 
1 2 
Cause of death in the non-neurosurgical group   
0.01 
   Brain death 5 8 
   Death with therapy withdrawn for severe   
cerebral damage 
4 15 
   Death with therapy withdrawn for non-cerebral 
reasons 
0 3 
   Death with maximal support for severe cerebral 
damage 
1 5 
   Death with maximal support for non-cerebral 
reasons 
1 3 
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Figure legends 
FIG. 1. Timing of cerebral and non-cerebral deaths in patients with moderate to severe 
traumatic brain injury.   
 
FIG.2. Survival curves for EPO and placebo groups according to whether patients had 
received a neurosurgical operation prior to randomisation or not.    
 
FIG.3. Post-hoc analysis of differential treatment effects of erythropoietin indexed by 
admission computed tomography scan findings.  
 
 
FIG.4. Post-hoc analysis of differential treatment effects of erythropoietin indexed by 
neurointensive care and neurosurgical interventions prior to randomisation and during ICU 
care.  
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Appendix 
SUPPLEMENTAL TABLE 1. A DETAILED EXPLORATION OF DIFFERENCES IN CLINICAL 
CHARACTERISTICS INDEXED BY CAUSE OF DEATH.  
*p<0.05 for comparison between causes of death 
 Brain death 
(n=16) 
Therapy 
withdrawn 
cerebral 
reason (n=39) 
Therapy 
withdrawn 
non-cerebral 
reason (n=8) 
Cerebral death 
during 
maximal 
support (n=7) 
Non-cerebral 
death during 
maximal 
support (n=7) 
Patient characteristics      
   Mean age (years)*
 
26 (22-45) 51 (24-59) 49 (44-59) 43 (24-48) 52 (25-58) 
   Female gender 3 (19%) 7 (18%) 1 (13%) 0 (0%) 3 (43%) 
Consciousness      
  Initial GCS
 
6 (4-7) 4 (3-7) 4 (4-9) 3 (3-8) 7 (4-10) 
Pupillary abnormality      
   Both equal and reacting 12 (75%) 25 (64%) 4 (50%) 5 (72%) 5 (71%) 
   Both dilated and non- 
reactive* 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (14%) 
  Both non-reactive 3 (19%) 5 (13%) 2 (25%) 1 (14%) 1 (14%) 
  One non-reactive 1 (6%) 8 (21%) 2 (25%) 1 (14%) 0 (0%) 
   Untestable/not 
documented 
0 (0%) 1 (3%) 0 (0%) 0 (0%) 0 (0%) 
Pre-hospital vital signs      
   Systolic blood pressure 
less than 90 mmHg 3 (19%) 17 (44%) 1 (13%) 3 (43%) 2 (29%) 
   Oxygen saturation less 
than 90% 5 (31%) 9 (23%) 1 (13%) 1 (14%) 2 (29%) 
Injury severity      
IMPACT probability of poor 
outcome 
37% (25-59%) 46% (28-59%) 37% (25-60%) 28% (24-65%) 23% (19-65%) 
APACHE II score  24 (20-28) 26 (20-33) 19 (15-26) 22 (21-22) 25 (16-28) 
Injury severity score 27 (22-35) 26 (21-34) 18 (11-30) 29 (21-33) 22 (20-45) 
Transfusion prior to 
randomisation 
     
   Red cells (%) 5 (31%) 15 (39%) 2 (25%) 1 (14%) 3 (43%) 
   Platelets (%) 1 (6%) 9 (23%) 2 (25%) 1 (14%) 1 (14%) 
   Fresh frozen plasma (%) 2 (13%) 8 (21%) 1 (13%) 1 (14%) 1 (14%) 
   Other clotting product (%) 0 (0%) 4 (10%) 0 (0%) 0 (0%) 1 (14%) 
   None (%) 11 (69%) 20 (51%) 5 (63%) 6 (86%) 4 (57%) 
Neurosurgical 
interventions 
     
   Mass lesion evacuated 4 (25%) 17 (44%) 3 (38%) 1 (14%) 2 (29%) 
   Craniectomy 2 (13%) 12 (31%) 3 (38%) 2 (29%) 3 (43%) 
   Bifrontal decompressive 
craniectomy 
1 (6%) 4 (10%) 0 (0%) 0 (0%) 0 (0%) 
ICU interventions      
   ICP use
 
13 (81%) 37 (95%) 8 (100%) 6 (86%) 5 (71%) 
   Proportion ICP end hours 
over 20 mmHg**
 
41% (22-62%) 10 % (5-24%) 3% (0-16%) 28% (11-46%) 10% (5-67%) 
  Hypothermia
 
8 (50%) 13 (33%) 2 (25%) 5 (71%) 2 (29%) 
  Hyperventilation used*
 
11 (69%) 33 (85%) 4 (50%) 5 (71%) 2 (29%) 
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SUPPLEMENTAL TABLE 2. A DETAILED EXPLORATION OF CAUSE OF DEATH INDEXED BY 
ADMISSION CT FINDINGS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Brain death 
(n=16) 
Therapy 
withdrawn 
cerebral reason 
(n=40) 
Therapy 
withdrawn non-
cerebral reason 
(n=8) 
Cerebral death 
during maximal 
support (n=7) 
Non-cerebral 
death during 
maximal 
support (n=7) 
CT findings      
   Subdural hematoma 11 (69%) 27 (69%) 5 (63%) 3 (43%) 6 (86%) 
   Extradural 
haematoma 
2 (13%) 7 (18%) 3 (38%) 1 (14%) 2 (29%) 
  Contusion 12 (75%) 29 (74%) 6 (75%) 7 (100%) 4 (57%) 
   Intracerebral 
haemorrhage 
9 (56%) 21 (54%) 5 (63%) 4 (57%) 1 (14%) 
   Subarachnoid 
haemorrhage 
16 (100%) 33 (85%) 6 (75%) 5 (72%) 6 (86%) 
   Intraventricular 
haemorrhage 
7 (44%) 20 (51%) 1 (14%) 5 (63%) 3 (43%) 
   Petechial 
haemorrhage 
7 (44%) 25 (64%) 4 (57%) 2 (25%) 1 (14%) 
   Midline shift (%) 9 (56%) 18 (46%) 4 (50%) 1 (14%) 5 (71%) 
   Midline shift (mm) 3 (0-6) 3 (0-7) 6 (0-9) 0 (0-2) 6 (2-7) 
   Basal cisterns** 
     Normal 
     Compressed 
     Absent 
 
5 (31%) 
10 (63%) 
1 (6%) 
 
16 (41%) 
20 (51%) 
3 (8%) 
 
4 (50%) 
3 (38%) 
1 (12%) 
 
4 (57%) 
3 (43%) 
0 (0%) 
 
3 (43%) 
4 (57%) 
0 (0%) 
Marshall category
 
 
   Diffuse injury I 
   Diffuse Injury II 
   Diffuse Injury III 
   Diffuse Injury IV  
   Evacuated mass 
lesion 
Non-evacuated mass 
lesion 
 
0 (0%) 
4 (25%) 
6 (38%) 
3 (19%) 
0 (0%) 
 
3 (19%) 
 
0 (0%) 
13 (33%) 
12 (31%) 
2 (5%) 
2 (5%) 
 
10 (26%) 
 
 
0 (0%) 
3 (38%) 
1 (12%) 
1 (12%) 
0 (0%) 
 
3 (38%) 
 
0 (0%) 
4 (57%) 
3 (43%) 
0 (0%) 
0 (0%) 
 
0 (0%) 
 
 
0 (0%) 
3 (43%) 
1 (14%) 
1 (14%) 
0 (0%) 
 
2 (29%) 
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SUPPLEMENTAL FIG.1. Survival curves for cerebral and non-cerebral deaths indexed by 
whether patients were treated with EPO or placebo.   
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SUPPLEMENTAL FIG.2. Distribution of neurological outcomes defined by the Glasgow 
Outcome Scale Extended in patients with a non-neurosurgically treated traumatic brain 
injury administered erythropoietin or placebo.     
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